| SEC Form 4 | 1 |
|------------|---|
|------------|---|

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden

0.5

hours per response:

| Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 |
|------------------------------------------------------------------------|
| |
| or Section 30(b) of the Investment Company Act of 1940 |

| 1. Name and Address of Reporting Person* | | | 2. Issuer Name and Ticker or Trading Symbol <u>ADMA BIOLOGICS, INC.</u> [ADMA] | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | |
|------------------------------------------|-----------------------------------------------------------------------------------------------------|----------|--------------------------------------------------------------------------------------------|-------------------------------|----------------------------------------------------------------------------|------------------|--|--|--|
| Giossinan | | | | X | Director | 10% Owner | | | |
| | | | | - | Officer (give title | Other (specify | | | |
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 09/10/2020 | | below) | below) | | | |
| C/O ADMA | rossman Jerrold B ast) (First) (Middle) /O ADMA BIOLOGICS, INC. 55 STATE ROUTE 17 reet) | | 09/10/2020 | | | | | | |
| 465 STATE I | POLITE 17 | | | | | | | | |
| +05 STATE I | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indi [,] Line) | ividual or Joint/Group Filing (Check Applicable | | | | |
| (Street) | | | | X | Form filed by One Re | eporting Person | | | |
| RAMSEY | NJ | 07446 | | | Form filed by More the Person | an One Reporting | | | |
| (City) | (State) | (Zip) | | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Disposed Of 5) | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership |
|---------------------------------|--------------------------------------------|-------------------------------------------------------------|-----------------------------------------|---|------------------------------------|---------------|--------|---------------------------------------------------------------------------|-------------------------------------------------------------------|-----------------------------------------------------|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (Instr. 4) |
| Common Stock | 09/10/2020 | | Р | | 5,000 | Α | \$2.22 | 160,864 ⁽¹⁾ | D | |
| Common Stock | | | | | | | | 22,857 | Ι | See Footnote ⁽²⁾ |
| Common Stock | | | | | | | | 31,381 | Ι | See Footnote ⁽³⁾ |
| Common Stock | | | | | | | | 38,294 | Ι | See Footnote ⁽⁴⁾ |
| Common Stock | | | | | | | | 175 | Ι | See Footnote ⁽⁵⁾ |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | (e.g., puts, cans, warrants, options, convertible securities) | | | | | | | | | | | | | | |
|-----------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------|-------------------------------------------------------------|------------------------------|---|------|-----|----------------------------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------|----------------------------------------|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of I | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |

Explanation of Responses:

1. Includes 3,750 RSUs granted on February 28, 2020 which remain unvested as of the date hereof and will become fully vested on February 28, 2021, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

2. These shares are owned by Brookwood LLC ("Brookwood"). The reporting person is the managing member of Brookwood.

3. These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.

4. These shares are owned by Genesis Foundation Inc. ("Genesis"). The reporting person is the President of Genesis.

5. These shares are owned by the reporting person's wife.

/s/ Dr. Jerrold B. Grossman,

by Brian Lenz as Attorney-in- 09/11/2020

fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).